vs

Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Usio, Inc. (USIO). Click either name above to swap in a different company.

Usio, Inc. is the larger business by last-quarter revenue ($22.2M vs $19.1M, roughly 1.2× NewAmsterdam Pharma Co N.V.). Usio, Inc. runs the higher net margin — -6.7% vs -90.7%, a 84.0% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 8.2%). Usio, Inc. produced more free cash flow last quarter ($1.1M vs $-37.8M).

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

Usio, Inc. is an American financial technology company headquartered in San Antonio, Texas. It provides integrated electronic payment services, including ACH processing, credit card and debit card acceptance, payment facilitation for software platforms, prepaid card issuing and a document print and mail operation.

NAMS vs USIO — Head-to-Head

Bigger by revenue
USIO
USIO
1.2× larger
USIO
$22.2M
$19.1M
NAMS
Growing faster (revenue YoY)
NAMS
NAMS
+731.9% gap
NAMS
740.1%
8.2%
USIO
Higher net margin
USIO
USIO
84.0% more per $
USIO
-6.7%
-90.7%
NAMS
More free cash flow
USIO
USIO
$38.8M more FCF
USIO
$1.1M
$-37.8M
NAMS

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
NAMS
NAMS
USIO
USIO
Revenue
$19.1M
$22.2M
Net Profit
$-17.4M
$-1.5M
Gross Margin
21.9%
Operating Margin
-186.1%
-5.7%
Net Margin
-90.7%
-6.7%
Revenue YoY
740.1%
8.2%
Net Profit YoY
55.5%
-337.8%
EPS (diluted)
$-0.15
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NAMS
NAMS
USIO
USIO
Q4 25
$22.2M
Q3 25
$21.2M
Q2 25
$19.1M
$20.0M
Q1 25
$22.0M
Q4 24
$12.8M
$20.6M
Q3 24
$29.1M
$21.3M
Q2 24
$20.1M
Q1 24
$21.0M
Net Profit
NAMS
NAMS
USIO
USIO
Q4 25
$-1.5M
Q3 25
$-415.1K
Q2 25
$-17.4M
$-366.7K
Q1 25
$-235.0K
Q4 24
$-92.2M
$628.9K
Q3 24
$-16.6M
$2.9M
Q2 24
$75.5K
Q1 24
$-250.2K
Gross Margin
NAMS
NAMS
USIO
USIO
Q4 25
21.9%
Q3 25
23.0%
Q2 25
25.8%
Q1 25
21.9%
Q4 24
24.6%
Q3 24
23.0%
Q2 24
23.9%
Q1 24
23.1%
Operating Margin
NAMS
NAMS
USIO
USIO
Q4 25
-5.7%
Q3 25
-2.2%
Q2 25
-186.1%
-2.0%
Q1 25
-1.1%
Q4 24
-338.5%
-2.9%
Q3 24
-85.9%
-1.8%
Q2 24
-1.0%
Q1 24
-1.3%
Net Margin
NAMS
NAMS
USIO
USIO
Q4 25
-6.7%
Q3 25
-2.0%
Q2 25
-90.7%
-1.8%
Q1 25
-1.1%
Q4 24
-721.7%
3.1%
Q3 24
-57.2%
13.4%
Q2 24
0.4%
Q1 24
-1.2%
EPS (diluted)
NAMS
NAMS
USIO
USIO
Q4 25
$-0.05
Q3 25
$-0.02
Q2 25
$-0.15
$-0.01
Q1 25
$-0.01
Q4 24
$-0.91
$0.03
Q3 24
$-0.18
$0.10
Q2 24
$0.00
Q1 24
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NAMS
NAMS
USIO
USIO
Cash + ST InvestmentsLiquidity on hand
$739.2M
$7.4M
Total DebtLower is stronger
$1.4M
Stockholders' EquityBook value
$778.5M
$17.9M
Total Assets
$815.1M
$134.9M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NAMS
NAMS
USIO
USIO
Q4 25
$7.4M
Q3 25
$7.7M
Q2 25
$739.2M
$8.1M
Q1 25
$8.7M
Q4 24
$834.2M
$8.1M
Q3 24
$422.7M
$8.4M
Q2 24
$7.2M
Q1 24
$7.1M
Total Debt
NAMS
NAMS
USIO
USIO
Q4 25
$1.4M
Q3 25
$836.7K
Q2 25
$647.1K
Q1 25
$683.3K
Q4 24
$719.4K
Q3 24
$562.9K
Q2 24
$597.2K
Q1 24
$630.9K
Stockholders' Equity
NAMS
NAMS
USIO
USIO
Q4 25
$17.9M
Q3 25
$18.7M
Q2 25
$778.5M
$18.7M
Q1 25
$19.0M
Q4 24
$757.5M
$19.2M
Q3 24
$378.9M
$18.9M
Q2 24
$15.7M
Q1 24
$15.3M
Total Assets
NAMS
NAMS
USIO
USIO
Q4 25
$134.9M
Q3 25
$99.4M
Q2 25
$815.1M
$108.4M
Q1 25
$109.6M
Q4 24
$864.6M
$107.2M
Q3 24
$439.2M
$114.6M
Q2 24
$108.8M
Q1 24
$99.1M
Debt / Equity
NAMS
NAMS
USIO
USIO
Q4 25
0.08×
Q3 25
0.04×
Q2 25
0.03×
Q1 25
0.04×
Q4 24
0.04×
Q3 24
0.03×
Q2 24
0.04×
Q1 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NAMS
NAMS
USIO
USIO
Operating Cash FlowLast quarter
$-37.7M
$1.5M
Free Cash FlowOCF − Capex
$-37.8M
$1.1M
FCF MarginFCF / Revenue
-197.2%
4.8%
Capex IntensityCapex / Revenue
0.5%
2.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-119.7M
$1.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NAMS
NAMS
USIO
USIO
Q4 25
$1.5M
Q3 25
$303.8K
Q2 25
$-37.7M
$-263.9K
Q1 25
$1.4M
Q4 24
$-37.5M
$2.9M
Q3 24
$-12.5M
$1.4M
Q2 24
$369.1K
Q1 24
$88.7K
Free Cash Flow
NAMS
NAMS
USIO
USIO
Q4 25
$1.1M
Q3 25
$85.2K
Q2 25
$-37.8M
$-503.2K
Q1 25
$1.1M
Q4 24
$-37.5M
$2.7M
Q3 24
$-12.6M
$1.4M
Q2 24
$246.3K
Q1 24
$-88.1K
FCF Margin
NAMS
NAMS
USIO
USIO
Q4 25
4.8%
Q3 25
0.4%
Q2 25
-197.2%
-2.5%
Q1 25
4.8%
Q4 24
-293.5%
13.1%
Q3 24
-43.2%
6.4%
Q2 24
1.2%
Q1 24
-0.4%
Capex Intensity
NAMS
NAMS
USIO
USIO
Q4 25
2.0%
Q3 25
1.0%
Q2 25
0.5%
1.2%
Q1 25
1.4%
Q4 24
0.0%
1.0%
Q3 24
0.3%
0.3%
Q2 24
0.6%
Q1 24
0.8%
Cash Conversion
NAMS
NAMS
USIO
USIO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
4.61×
Q3 24
0.50×
Q2 24
4.89×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NAMS
NAMS

Segment breakdown not available.

USIO
USIO

Credit Card Revenue$7.7M35%
ACH And Complementary Service Revenue$6.1M28%
Output Solutions$5.4M24%
Prepaid Card Services Revenue$2.6M12%

Related Comparisons